Last reviewed · How we verify
furosemide infusion
At a glance
| Generic name | furosemide infusion |
|---|---|
| Also known as | Continuous vs intermittent intravenous furosemide infusion |
| Sponsor | Reprieve Cardiovascular, Inc |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study (PHASE4)
- Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers (PHASE1)
- Comparison of the Effectiveness of Different Diuretic Therapies in the Management of Acute Heart Failure (NA)
- Comparison of Plasma Neutrophil Gelatinase-Associated Lipocalin (pNGAL) Level in De-resuscitation With Furosemide Group and Control Group (NA)
- "Effect of Albumin Combined With Furosemide in Critically Ill Patients With Fluid Overload: Impact on Urine Output and Renal Function" (NA)
- Reprieve System Pilot Study (NA)
- A Study of Ultra High Dose Diuretics to Treat Heart Failure (PHASE2)
- Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |